[1] | Kramer MS, Demissie K, Yang H, Platt RW, Sauve R, Liston R. The contribution of mild and moderate preterm birth to infant mortality. Fetal and Infant Health Study Group of the Canadian Perinatal Surveillance System. JAMA. 2000; 284(7): 843–849. |
[2] | Hermansen CL, Lorah KN. Respiratory distress in the newborn. Am Fam Physician. 2007; 76(7):987–994. |
[3] | Dani C, Bertini G, Pezzati M, Cecchi A, Caviglioli C, Rubaltelli FF. Early extubation and nasal continuous positive airway pressure after surfactant treatment for respiratory distress syndrome among preterm infants <30 weeks' gestation. Pediatrics. 2004; 113(6):e560–563. |
[4] | Bustani P, Hodge R, Tellabati A, Li J, Pandya H, Kotecha S. Differential response of the epithelium and interstitiumindeveloping human fetal lung explants to hyperoxia. Pediatr Res. 2006;59:383–388. |
[5] | Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003; 253:269–285. |
[6] | Fukuda Y, Ishizaki M, Okada Y, Seiki M, Yamanaka N. Matrixmetalloproteinases and tissue inhibitor of metalloproteinase-2 in fetal rabbit lung. Am J Physiol Lung Cell Mol Physiol. 2000;279: 555–561. |
[7] | Van Lint P, Libert C. Chemokine and cytokine processing by matrixmetalloproteinases and its effect on leukocyte migration andinflammation. J LeukocBiol 2007;82:1375–81. |
[8] | Cederqvist K, Sorsa T, Tervahartiala T, Maisi P, Reunanen K, Lassus P, Andersson S. Matrix metalloproteinases-2, -8, and -9 and TIMP-2 in tracheal aspirates from preterm infants with respiratory distress. Pediatrics 2001; 108: 686-692. |
[9] | Sezer RG, Aydemir G, Bozaykut A, Hira S, Tanju IA, Özcan Ö. The relationship between the first episode of wheezing and matrix metalloproteinases-9 and MMP-2 and tissue inhibitors of MMP-1 levels in preterm infants. Ann Thorac Med. 2013;8:209-213. |
[10] | Vandooren J, Van den Steen PE, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade. Critical Reviews in Biochemistry and Molecular Biology. 2013; 48(3): 222-272. |
[11] | Sweet DG, Curley AD, Chesshyre E, Pizzotti J, Wilbourn MS, Halliday HL, Warner JA. The role of matrix mealloproteinases 9 and 2 in development of neonatal chronic lung disease. ActaPaediatr. 2004;93:791–796. |
[12] | Harijith A, Choo-Wing R, Cataltepe S, Yasumatsu R, Aghai ZH, Janér J, Andersson S, Homer RJ, Bhandari V. A Role for Matrix Metalloproteinase 9 in IFNγ-Mediated Injury in Developing Lungs. American Journal of Respiratory Cell and Molecular Biology. 2011; 44(5): 621-630. |
[13] | Kramer MS, Platt R, Yang H, Joseph KS, Wen SW, Morin L, Usher RH. Secular trends in preterm birth: a hospital-based cohort study. JAMA 1998; 280: 1849–1854. |
[14] | Ballard JL, Khoury JC (1991). New Ballard score, expanded to include extremely premature infants. J Pediatrics; 119: 417-423. |
[15] | Kirkpatrick B, Mueller D. Respiratory disorders in newborn. In: Chernick V, Boat T, Edwin L (eds) Kendig’s. Disorders of the Respiratory Tract in Children. WB Saunders: Philadelphia, 1988. p. 328-64. |
[16] | Liu J. Respiratory distress syndrome in full-term neonates. Neonatal Biol. 2012; 2167-0897. |
[17] | Newman B. Imaging of medical disease of the newborn lung. RadiolClin North Am. 1999;37:1049-78. |
[18] | Greenough A, Roberton NRC. Acute respiratory disease in the newborn. In: Rennie JM, Roberton NRC, editors. Textbook of neonatology. 3rd ed. Edinburgh: Churchill Livingstone 2000; pp 481–607. |
[19] | Rodriguez RJ, Martin RJ, Fanaroff AA. Respiratory distress syndrome and its management. In: Fanaroff AA, Martin RJ, editors. Neonatal-perinatal medicine, diseases of the fetus and infant. 7th ed. St Louis: Mosby; 2002.pp 1001–1085. |
[20] | Bomsel F. Contribution al'etuderadiologique de la maladiedes membranes hyalines. A propos de 110 cas. J RadiolElectrol 1970;51:259-68. |
[21] | Chung YH, Park YJ, Bae CW, Sung DW. Correlation between Chest Radiographic Findings and Respiratory Indices in Neonates with Respiratory Distress Syndrome. Korean J Pediatr 2003 July;46(7) :655-660. |
[22] | Thiennu H. Vu and Zena Werb. Matrix metalloproteinases: effectors of development and normal physiology. Genes & Dev. 2000; 14: 2123-2133. |
[23] | Laudy JA, Wladimiroff JW. The fetal lung: Developmental aspects. Ultrasound ObstetGynecol 2000; 16:284–290. |
[24] | Fukuda Y, Ishizaki M, Okada Y, Seiki M, Yamanaka N. Matrixmetalloproteinases and tissue inhibitor of metalloproteinase-2 in fetal rabbit lung. Am J Physiol Lung Cell MolPhysiol 2000; 279: 555–561. |
[25] | Chakrabarti S and Patel KD. Matrix metalloproteinases (MMP-2) and MMP-9 in pulmonary pathology. Experimental Lung Research 2005; 31:599–621. |
[26] | Brauer PR. MMPs – role in cardiovascular development and disease. FrontBiosci 2006;11:447–78. |
[27] | Kheradmand F, Rishi K, Werb Z. Signaling through the EGFreceptor controls lung morphogenesis in part by regulatingMT1-MMP-mediated activation of gelatinase A/MMP2. J Cell Sci2002;115:839–48. |
[28] | Leung-Pineda V and Gronowski AM. Biomarker tests for fetal lung maturity. Biomarkers Med.2010; 4(6), 849–857 |
[29] | Profita M, Gagliardo R, Di Giorgi R, Bruno A, Riccobono L, Bonanno A, Bousquet J, Vignola AM. In vitro effects of flunisolide on MMP-9, TIMP-1, fibronectin, TGF-beta1 release and apoptosis in sputum cells freshly isolated from mild to moderate asthmatics. Allergy 200459:927–932. |
[30] | Matoba N, Yu Y, Mestan K, Pearson C, Ortiz K, Porta N, Thorsen P, Skogstrand K, Hougaard DM, Zuckerman B, Wang X. Differential Patterns of 27 Cord Blood Immune Biomarkers Across Gestational Age. Pediatrics 2009; 123; 1320-1328. |
[31] | Kaukola T, Tuimala J, Herva R, Kingsmore S, Hallman M. Cord immunoproteins as predictors of respiratory outcome in preterm infants. Am J ObstetGynecol 2009; 200: 100.e1-100.e8. |
[32] | Kraljevic D, Vukojevic K, Karan D, Rajic B, Todorovic J, Miskovic J, Tomic V, Kordic, Soljic V. Proliferation, apoptosis and expression of matrix metalloproteinase-9 in human fetal lung. ActaHistochemica. 2015; 117: 444–450. |
[33] | Dik WA, van Kaam AH, Dekker T, Naber BA, Janssen DJ, Kroon AA, Zimmermann LJ, Versnel MA, Lutter R. Early increased levels of matrix metalloproteinase‑9 in neonates recovering from respiratory distress syndrome. Biol Neonate 2006; 89:6‑14. |
[34] | Natarajan G, Shankaran S, McDonald SA, Das A, Stoll BJ, Higgins RD, Thorsen P, Skogstrand K, Hougaard DM , Carlo WA. Circulating beta chemokine and MMP 9 as markers of oxidative injury in extremely low birth weight infants. Pediatr Res 2010;67:77‑82. |
[35] | Sezer RG, Aydemir G, Bozaykut A, Hira S, Tanju IA, Özcan Ö. The relationship between the first episode of wheezing and matrix metalloproteinases-9 and MMP-2 and tissue inhibitors of MMP-1 levels in preterm infants. Ann Thorac Med 2013; 8: 209-213. |
[36] | Schulz CG, Sawicki G, Lemke RP, Roeten BM, Schulz R, Cheung PY. MMP‑2 and MMP‑9 and their tissue inhibitors in the plasma of preterm and term neonates. Pediatr Res 2004;55:794‑801. |